Supriya Lifescience is down 10% today The fall is mainly due to a disclosure regarding judicial proceedings involving one of the company’s personnel Proceedings have been initiated against Mr. Sreekant Sreedharan, General Manager - Sales & Marketing, by the Special Investigation & Intelligence Branch of the Customs Department The matter is under the NDPS Act, 1985 & relates to a procedural lapse in a single export transaction of an identified product The company has clarified that, based on the information currently available, the proceedings are not expected to have any material impact on its operations However, since the matter involves customs, market seems to be reacting cautiously For now, this is not a business performance issue, but a governance / compliance related issue

🚨 Supriya Lifescience Share Crash! 📉 ₹1,085 से सीधा ₹863! क्या यह NDPS Case का डर है या Valuation Bubble ब्लास्ट हुआ है? क्या ₹800 का सपोर्ट ज़ोन स्टॉक को बचा पाएगा? पैनिक करने से पहले Buy, Sell या Hold का पूरा सच जानिए: 👇 🔗 youtu.be/Kfkw5pc19L8

Zurich lancia una soluzione assicurativa dedicata al settore Life Science intermediachannel.it/2026/07… #Zurich #assicurazioni #lifescience #prodotti

MARKET CLOSING UPDATE - 06-07-2026 📊 Nifty 50: 24,430.35 ▲ 159.50 ( 0.66%) Bank Nifty: 58,291.50 ▲ 353.00 ( 0.61%) Sensex: 78,285.07 ▲ 521.16 ( 0.67%) MidCap: 16,857.05 ▲ 78.77 ( 0.47%) SmallCap: 7,146.61 ▲ 26.22 ( 0.37%) TOP GAINERS: Lloyds Engg. Works 8.33% TD Power Systems 8.14% Allied Blenders 7.15% 63 Moons Tech 7.07% Texmaco Rail 7.03% TOP LOSERS: Supriya Lifescience -11.62% PC Jeweller -8.33% Zensar Technologies -7.60% Apollo Micro -5.75% Acutaas Chemicals -4.78% For educational purpose only. #MarketUpdate #Nifty #BankNifty #Sensex #StockMarket

Stocks to Watch Today: Supriya Lifescience, Rubicon Research, Fortis Healthcare, Fermenta Biotech Source: ift.tt/MRWvjCO Get daily free stock ideas at t.me/stockinvesta #StockMarket #BreakoutStocks #StockToWatch #StocksToBuy

🚨 Supriya Lifescience Update Supriya Lifescience informed the stock exchanges that its General Manager (Sales & Marketing) is facing a customs dept investigation. The court has granted judicial custody until July 17, 2026. The company said it continues to follow all regulatory rules and will share further updates if needed. Investors should watch for any future disclosures before drawing conclusions. #Stocks #SupriyaLifescience #StockMarket #India #Nifty

📢On-Demand Webinar! Perfect for FIB-SEM/EBSD users and battery researchers✨ Learn how to prepare TEM lamellae with controlled orientation and protect sensitive materials with air‑isolation transfer. 📅Date:Aug 19 (Wed) to Aug 21 (Fri), 2026 -JST, on-demand ▼Details ＆Registration: jeol.com/events_seminars/sem… We look forwarad to your joining us! #SEM #TEM #LifeScience #Battery #JEOL_Webinar #JEOL

The recent arrest of a senior executive at Supriya Lifescience has definitely sent ripples through the market, especially given the company's heavy reliance on international trade. Here is a breakdown of what happened and the immediate impact on the company and its stock. What Exactly Happened? On July 3, 2026, Sreekant Sreedharan, the General Manager of Sales & Marketing at Supriya Lifescience, was arrested by the Special Investigation and Intelligence Branch of the Customs Department. He has been placed in judicial custody until July 17, 2026. The arrest was made under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. It stems from an alleged attempt to export 200 kg of Ketamine Hydrochloride (a controlled substance) to South Korea using an expired Central Bureau of Narcotics export authorization. The Impact Breakdown 1. Market Reaction and Stock Price The market reacted negatively to the sudden governance and regulatory risk. On July 6, 2026, Supriya Lifescience's stock dropped by roughly 5.6% to around ₹923.70. In the near term, the market is likely to apply a "governance risk premium" to the stock until there is absolute clarity that this is an isolated incident. 2. The Company's Official Stance Supriya Lifescience filed a regulatory disclosure stating that this was a "procedural lapse" involving a single export transaction. They have maintained that, based on current information, they expect no material impact on their daily operations, financial position, or corporate governance. They are actively seeking legal counsel to navigate the proceedings. 3. Operational and Export Risks This is where the real concern lies for investors. Supriya Lifescience is a highly export-oriented API (Active Pharmaceutical Ingredient) player, generating roughly 75-80% of its revenue from exports to over 85 countries. * Leadership Void: Having the head of Sales & Marketing in custody for two weeks creates immediate friction in export strategy and customs-related clearances. * Regulatory Scrutiny: The pharmaceutical export business relies heavily on seamless customs compliance. Even if this turns out to be a purely local documentation error, there is a risk that it could lead to heightened scrutiny from global regulators or cause procedural delays in their supply chain, leading to temporary inventory build-ups. Ultimately, while the company maintains that its core manufacturing operations are unaffected, the market is pricing in the uncertainty of having a key export executive tied up in an NDPS investigation. It is definitely a situation to monitor closely, especially regarding any further regulatory disclosures from the company. Disclaimer: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. It is for educational purposes only. #supriya #Lifesciences #arrest #ndps #customs

🚨Corporate Disclosure | Supriya Lifescience Supriya Lifescience has made a regulatory disclosure regarding judicial proceedings involving its General Manager (Sales & Marketing). The company emphasized that it is monitoring the matter closely and will provide updates in accordance with SEBI's disclosure requirements. #StockMarket #SupriyaLifescience #CorporateNews #SEBI #BSE #NSE #IndianStocks #MarketUpdate

#StockInNews | Supriya Lifescience says its GM of Sales & Marketing has been remanded to judicial custody in an NDPS Act case linked to a single export transaction @Meryldsouza_ brings you the details #SupriyaLifescience #NDPS #CorporateUpdate

🔥 Stock Tigers Watchlist | 06 July 2026 🔥 ✅ 3 Powerful Stocks 🚀 Stock No. 1 – Multiyear Breakout:- Shilpa Medicare 📊 Stock No. 2 – Multiyear Breakout :- Aegis Logistics 💰 Stock No. 3 – BONUS STOCK :- Suven Lifescience For Analysis Watch the YT vidoe

don't tell them Daihan and JW Lifescience are oligopolies and have insider buying this year!

Supriya Lifescience down 9.76% to Rs 884 in early trade. The trigger: Judicial proceedings initiated against senior official under NDPS Act.